The Association of Glucocorticosteroid Treatment with WBC Count in Patients with COPD Exacerbation
Systematic glucocorticosteroids (GCS) are used to treat chronic obstructive pulmonary disease (COPD) and can cause leukocytosis. Distinguishing the effect of GCS on leukocyte level from infection-induced leukocytosis is important. We sought to quantify the effect of chronic GCS treatment on leukocyt...
Main Authors: | Amit Frenkel, Eric Kachko, Victor Novack, Moti Klein, Evgeni Brotfain, Leonid Koyfman, Nimrod Maimon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/10/1697 |
Similar Items
-
Effect of systemic glucocorticosteroids in the management of asthma and chronic obstructive pulmonary disease exacerbation on respiratory microbiota composition in the period of stability
by: S. V. Fedosenko, et al.
Published: (2017-01-01) -
Decline of COPD exacerbations in clinical trials over two decades – a systematic review and meta-regression
by: Stefan Andreas, et al.
Published: (2019-08-01) -
Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD
by: Mike Lonergan, et al.
Published: (2020-07-01) -
Eosinophilic inflammation in chronic obstructive pulmonary disease
by: S N Avdeev, et al.
Published: (2019-10-01) -
Pharmacological Treatment in Asthma and COPD
by: Tomoaki Hoshino, et al.
Published: (2009-01-01)